Enzymatica has concluded its first commercial agreement. This entails that Enzymatica’s medical device product, ColdZyme® Mouth Spray used against the common cold, will be on sale at the Kronans Droghandel pharmacies in early 2013.
“The agreement is, of course, commercially important for us, since the pharmacy chains represent a significant factor in our launch strategy. It has been consistently our goal to launch among the pharmacy chains at the beginning of 2013 and thus it is extra gratifying to be able to deliver
on schedule,” says Michael Edelborg Christensen, CEO at Enzymatica.
The agreement means Enzymatica’s registered product, ColdZyme® Mouth Spray, will be on sale at the Kronans Droghandel pharmacies nationwide. The launch of the ColdZyme® Mouth Spray is expected to take place at the end of January 2013.
“That we have in such a short period from the registration of the product secured the first agreement with a major pharmacy chain, we regard as a stamp of quality for our products and confirmation of the
market potential. Negotiations with other pharmacy chains are proceeding as planned,” notes Michael Edelborg Christensen.
For more information, contact:
Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
Andreas Rosenlund, Director of Information at Kronans Droghandel, 0703-59 10 58